Pharmaceutical

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Keytruda in recurrent HNSCC is planned for H2 this year.

May 29, 2024 - 04:00
ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC
A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Keytruda in recurrent HNSCC is planned for H2 this year.
Read the original article

Tags:

Previous Article

ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient de...

Next Article

Asahi Kasei offers to buy Sweden’s Calliditas for $1.04bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA greenlights medical device to combat bladder issues

FDA greenlights medical device to combat bladder issues

Aug 23, 2023

Plocabulin by Pharma Mar for Peritoneal Cancer: Likelih...

Nov 16, 2023

STAT+: Evelo Biosciences, a microbiome company launched by Flagship, shuts down

STAT+: Evelo Biosciences, a microbiome company launched...

Nov 23, 2023